로타바이러스 예방 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.9%로 성장할 전망이며, 146억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 소화기 질환 부담, 세계 확대, 백신 접종 프로그램 및 백신의 신뢰성에 기인하고 있습니다. 예측 기간 주요 동향에는 차세대 백신, 혼합 백신, 백신 전달 혁신 및 세계 예방접종 협력 등이 있습니다.
로타바이러스 예방 시장의 성장은 백신 코스 증가로 이어질 것으로 예상됩니다. 백신 코스는 특정 질환에 대한 예방을 목적으로 한 백신의 특정 용량으로 구성되며, 로타바이러스 감염과의 싸움에서 매우 중요한 역할을 합니다. 백신 코스의 용량은 면역학적 반응의 촉매로 작용하여 로타바이러스에 대한 면역력을 현저하게 높이고 질병의 위험을 줄입니다. 이에 따라 백신의 유효성이 전체적으로 높아집니다. 예로서 2022년 1월에 발표된 유엔 국제아동긴급기금(UNICEF)의 보고에 따르면 2022년에는 약 571만 코스의 RV1-5 냉동 로타바이러스 백신이 제조되었으며, 2028년에는 931만 코스로 급증할 것으로 예측되고 있습니다. 게다가 2022년에는 529만 코스의 RV5-2 동결 건조 로타바이러스 백신이 제조되었으며, 2028년에는 613만 코스로 증가할 것으로 예측되고 있습니다. 그 결과, 백신 입수 가능성이 높아지는 것이 로타바이러스 예방 시장의 원동력이 될 것으로 생각됩니다.
로타바이러스 예방 시장은 기관 투자자의 자금 조달에 의해 큰 성장이 예상됩니다. 기관에 대한 자금 지원이란 다양한 프로그램, 요구, 프로젝트를 지원하기 위한 재정적, 인적, 물적 자원의 할당을 의미합니다. 로타바이러스 이환율이 상승하고 있는 것으로부터, 정부 기관 및 민간 단체로부터의 자금 원조가 모여 있습니다. 이 자금 지원에는 금전적 원조 및 기술적 원조 모두가 있으며, 로타바이러스 백신과 내복약 개발의 다양한 단계에 걸쳐 있습니다. 그 일례로서 2022년 4월, 미국의 공립 연구 대학인 인디애나 대학은, 벤처 캐피탈 GIVAX Inc.로부터 120만 달러의 조성금을 획득했습니다. 이 조성금은, 로타바이러스와 노로바이러스를 조합한 영유아용 경구 백신의 혁신적 기술의 개발을 촉진하는 것을 목적으로 하고 있습니다. 이 획기적인 기술은 기존 로타바이러스 백신의 범위를 확대하고 유아에게 심한 구토나 설사를 일으키는 감염력이 강한 바이러스인 노로바이러스에 대한 방어를 포함하는 것입니다. 따라서, 자금원의 이용 가능성의 증대는, 로타바이러스 예방약 시장을 추진할 태세를 갖추고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 로타바이러스 예방 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 로타바이러스 예방 시장 : 성장률 분석
- 세계의 로타바이러스 예방 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 로타바이러스 예방 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 로타바이러스 예방 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 로타바이러스 예방 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 로타릭스
- 로타백
- 로타빈 M1
- 경구 보수액
- 기타 치료법
- 세계의 로타바이러스 예방 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 오랄
- 비경구
- 기타 투여 경로
- 세계의 로타바이러스 예방 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타 유통 채널
- 세계의 로타바이러스 예방 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 홈케어
- 기타 최종 사용자
- 세계의 로타바이러스 예방 시장 : 로타릭스 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 단회 투여
- 멀티 도즈
- 세계의 로타바이러스 예방 시장 : 로터리식 백신별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 액체 제형
- 동결 건조 제제
- 세계의 로타바이러스 예방 시장 : 로타빈 M1별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 액체 제형
- 동결 건조 제제
- 세계의 로타바이러스 예방 시장 : 경구 보수액 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 전해질 용액
- 포도당 기반 솔루션
- 세계의 로타바이러스 예방 시장 : 기타 치료법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 지지요법
- 설사제약
제7장 지역별 및 국가별 분석
- 세계의 로타바이러스 예방 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 로타바이러스 예방 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 로타바이러스 예방 시장 : 경쟁 구도
- 로타바이러스 예방 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Astra Zeneca Pharmaceuticals LP
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Sinovac Biotech Ltd.
- Astellas Pharma Inc.
- CSL Limited
- Bharat Biotech International Limited
- Daiichi Sankyo Co. Ltd.
- Lupin Limited
- Mitsubishi Tanabe Pharma Corporation
- Serum Institute of India Pvt. Ltd.
- Zydus Lifescience Ltd.
- Emergent BioSolutions Inc.
- Hualan Biological Engineering Inc.
- Biocad Biopharmaceutical Co.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 로타바이러스 예방 시장 : 새로운 기회를 제공하는 국가(2029년)
- 로타바이러스 예방 시장 : 새로운 기회를 제공하는 부문(2029년)
- 로타바이러스 예방 시장 : 성장 전략(2029년)
제36장 부록
AJY
Rotavirus prophylaxis involves the prevention of rotavirus infection through vaccination, aiming to shield infants and young children from this highly contagious illness that triggers inflammation in the stomach and bowels. The primary objective is to provide protection against the infection's severity.
The primary methods employed for rotavirus prophylaxis include the administration of vaccines such as Rotarix, Rotavac, Rotavin-M1, as well as the utilization of oral rehydration fluids, among other interventions. Rotavirus, a viral agent, is responsible for inducing severe stomach and intestinal disorders, often characterized by symptoms like fever, vomiting, and diarrhea. These interventions are deployed through various routes of administration, including oral and parenteral methods, and are readily accessible through outlets such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The intended beneficiaries of these preventive measures encompass hospitals, specialty clinics, home care services, and various other healthcare settings.
The rotavirus prophylaxis market research report is one of a series of new reports from The Business Research Company that provides rotavirus prophylaxis market statistics, including rotavirus prophylaxis industry global market size, regional shares, competitors with a rotavirus prophylaxis market share, detailed rotavirus prophylaxis market segments, market trends and opportunities and any further data you may need to thrive in the rotavirus prophylaxis industry. This rotavirus prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $9.05 billion in 2024 to $10.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.
The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $14.63 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.
The growth of the rotavirus prophylaxis market is anticipated to be powered by the rising number of vaccine courses. A vaccine course, which consists of specific doses of a vaccine designed to confer protection against a particular disease, plays a pivotal role in the battle against rotavirus infection. The vaccine course dosage acts as a catalyst for the immunological response, significantly enhancing immunity against rotavirus and reducing the risk of illness. This leads to an overall increase in vaccine efficacy. As an illustration, a report by the United Nations International Children's Emergency Fund (UNICEF) published in January 2022 revealed that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were manufactured in 2022, with a projected surge to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with an expected rise to 6.13 million courses by 2028. Consequently, the growing availability of vaccines will be a driving force behind the rotavirus prophylaxis market.
The rotavirus prophylaxis market is expected to experience significant growth fueled by institutional funding. Institutional funding entails the allocation of financial, human, or material resources to support various programs, needs, or projects. The escalating incidence of rotavirus cases has attracted funding from government bodies and private organizations. This financial support encompasses both monetary and technical assistance, spanning different stages of rotavirus vaccine and oral medication development. To exemplify, in April 2022, Indiana University, a public research university based in the United States, secured a $1.2 million grant from the venture capital firm GIVAX Inc. The grant aims to facilitate the development of innovative technology for a combined oral rotavirus-norovirus vaccine for infants. This groundbreaking technology expands the scope of the existing rotavirus vaccine to include protection against norovirus, a highly contagious virus responsible for severe vomiting and diarrhea in young children. Therefore, the increased availability of funding sources is poised to propel the rotavirus prophylaxis market.
Prominent companies operating in the rotavirus prophylaxis market are actively engaged in vaccine development to meet the evolving demands of consumers. The process of vaccine approvals involves a rigorous and multi-stage development and testing procedure. These approvals are essential in ensuring the safety and effectiveness of vaccines for preventing this viral disease, especially in infants and young children. For instance, in November 2022, GlaxoSmithKline PLC, a U.K.-based pharmaceutical and biotechnology company, announced the approval by the Food and Drug Administration (FDA) of an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral). This vaccine prevents rotavirus gastroenteritis in infants, caused by G1 and non-G1 types (G3, G4, and G9). The novel oral-dosing applicator-only presentation is entirely liquid and should not be reconstituted before use. Both ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, containing the same live, human-attenuated rotavirus strain and manufactured using similar methods.
In August 2022, Aspen Pharmacare Holdings Limited (APN), a South Africa-based pharmaceutical company, entered into a strategic collaboration with Serum Institute of India Pvt. Ltd. The partnership with the Serum Institute of India (SII) aimed to manufacture and distribute four Aspen-branded vaccines in Africa. This collaboration sought to bolster Africa's health manufacturing capacity and provide affordable vaccine access to the African population. Serum Institute of India Pvt. Ltd. is a vaccine manufacturer based in India, including vaccines for rotavirus.
Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rotavirus prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rotavirus prophylaxis market consists of revenues earned by entities by providing services such as vaccination, clinical management, awareness programs and diagnosis. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rotavirus Prophylaxis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rotavirus prophylaxis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rotavirus prophylaxis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rotavirus prophylaxis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
- 2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
- 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
- 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
- Subsegments:
- 1) By Rotarix: Single Dose; Multi-Dose
- 2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation
- 3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation
- 4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions
- 5) By Other Treatments: Supportive Care; Antidiarrheal Medications
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co.; Novartis AG; Sanofi SA
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Rotavirus Prophylaxis Market Characteristics
3. Rotavirus Prophylaxis Market Trends And Strategies
4. Rotavirus Prophylaxis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Rotavirus Prophylaxis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Rotavirus Prophylaxis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Rotavirus Prophylaxis Market Growth Rate Analysis
- 5.4. Global Rotavirus Prophylaxis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Rotavirus Prophylaxis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Rotavirus Prophylaxis Total Addressable Market (TAM)
6. Rotavirus Prophylaxis Market Segmentation
- 6.1. Global Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rotarix
- Rotavac
- Rotavin-M1
- Oral Rehydration Fluid
- Other Treatments
- 6.2. Global Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Route of Administrations
- 6.3. Global Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other Distribution Channels
- 6.4. Global Rotavirus Prophylaxis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- Other End-Users
- 6.5. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotarix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single Dose
- Multi-Dose
- 6.6. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavac, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Liquid Formulation
- Freeze-Dried Formulation
- 6.7. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavin-M1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Liquid Formulation
- Freeze-Dried Formulation
- 6.8. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Oral Rehydration Fluid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Electrolyte Solutions
- Glucose-Based Solutions
- 6.9. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Supportive Care
- Antidiarrheal Medications
7. Rotavirus Prophylaxis Market Regional And Country Analysis
- 7.1. Global Rotavirus Prophylaxis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Rotavirus Prophylaxis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Rotavirus Prophylaxis Market
- 8.1. Asia-Pacific Rotavirus Prophylaxis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Rotavirus Prophylaxis Market
- 9.1. China Rotavirus Prophylaxis Market Overview
- 9.2. China Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Rotavirus Prophylaxis Market
- 10.1. India Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Rotavirus Prophylaxis Market
- 11.1. Japan Rotavirus Prophylaxis Market Overview
- 11.2. Japan Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Rotavirus Prophylaxis Market
- 12.1. Australia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Rotavirus Prophylaxis Market
- 13.1. Indonesia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Rotavirus Prophylaxis Market
- 14.1. South Korea Rotavirus Prophylaxis Market Overview
- 14.2. South Korea Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Rotavirus Prophylaxis Market
- 15.1. Western Europe Rotavirus Prophylaxis Market Overview
- 15.2. Western Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Rotavirus Prophylaxis Market
- 16.1. UK Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Rotavirus Prophylaxis Market
- 17.1. Germany Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Rotavirus Prophylaxis Market
- 18.1. France Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Rotavirus Prophylaxis Market
- 19.1. Italy Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Rotavirus Prophylaxis Market
- 20.1. Spain Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Rotavirus Prophylaxis Market
- 21.1. Eastern Europe Rotavirus Prophylaxis Market Overview
- 21.2. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Rotavirus Prophylaxis Market
- 22.1. Russia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Rotavirus Prophylaxis Market
- 23.1. North America Rotavirus Prophylaxis Market Overview
- 23.2. North America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Rotavirus Prophylaxis Market
- 24.1. USA Rotavirus Prophylaxis Market Overview
- 24.2. USA Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Rotavirus Prophylaxis Market
- 25.1. Canada Rotavirus Prophylaxis Market Overview
- 25.2. Canada Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Rotavirus Prophylaxis Market
- 26.1. South America Rotavirus Prophylaxis Market Overview
- 26.2. South America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Rotavirus Prophylaxis Market
- 27.1. Brazil Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Rotavirus Prophylaxis Market
- 28.1. Middle East Rotavirus Prophylaxis Market Overview
- 28.2. Middle East Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Rotavirus Prophylaxis Market
- 29.1. Africa Rotavirus Prophylaxis Market Overview
- 29.2. Africa Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Rotavirus Prophylaxis Market Competitive Landscape And Company Profiles
- 30.1. Rotavirus Prophylaxis Market Competitive Landscape
- 30.2. Rotavirus Prophylaxis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
31. Rotavirus Prophylaxis Market Other Major And Innovative Companies
- 31.1. Astra Zeneca Pharmaceuticals LP
- 31.2. GlaxoSmithKline plc
- 31.3. Takeda Pharmaceutical Company Limited
- 31.4. Sinovac Biotech Ltd.
- 31.5. Astellas Pharma Inc.
- 31.6. CSL Limited
- 31.7. Bharat Biotech International Limited
- 31.8. Daiichi Sankyo Co. Ltd.
- 31.9. Lupin Limited
- 31.10. Mitsubishi Tanabe Pharma Corporation
- 31.11. Serum Institute of India Pvt. Ltd.
- 31.12. Zydus Lifescience Ltd.
- 31.13. Emergent BioSolutions Inc.
- 31.14. Hualan Biological Engineering Inc.
- 31.15. Biocad Biopharmaceutical Co.
32. Global Rotavirus Prophylaxis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Rotavirus Prophylaxis Market
34. Recent Developments In The Rotavirus Prophylaxis Market
35. Rotavirus Prophylaxis Market High Potential Countries, Segments and Strategies
- 35.1 Rotavirus Prophylaxis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Rotavirus Prophylaxis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Rotavirus Prophylaxis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
